Page 51 - Read Online

Page 10 of 11 Pica et al. Vessel Plus 2022;6:10 https://dx.doi.org/10.20517/2574-1209.2021.81

preserved ejection fraction. Eur Heart J 2015;36:2585-94. DOI PubMed
5. Bennani Smires Y, Victor G, Ribes D, et al. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart
failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int J Cardiovasc Imaging 2016;32:1403-13.
DOI PubMed
6. Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with
severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:2879-87. DOI PubMed PMC
7. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286-300. DOI PubMed PMC
8. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification
International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 2016;23:209-13. DOI PubMed
9. Pellikka PA, Holmes DR Jr. , Edwards WD, et al. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected
cardiac involvement. Arch Intern Med 1988;148:662-6. PubMed
10. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for
multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization. J Card Fail 2019;25:854-65.
DOI PubMed
11. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.
DOI PubMed
12. Hamer JP, Janssen S, van Rijswijk MH, Lie KI. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical,
echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J
1992;13:623-7. DOI PubMed
13. Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac
amyloidosis. Circulation 2014;129:1840-9. DOI PubMed
14. Phelan D, Collier P, Thavendiranathan P, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking
echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012;98:1442-8. DOI PubMed
15. Williams LK, Forero JF, Popovic ZB, et al. Patterns of CMR measured longitudinal strain and its association with late gadolinium
enhancement in patients with cardiac amyloidosis and its mimics. J Cardiovasc Magn Reson 2017;19:61. DOI PubMed PMC
99m
16. Löfbacka V, Axelsson J, Pilebro B, Suhr OB, Lindqvist P, Sundström T. Cardiac transthyretin amyloidosis Tc-DPD SPECT
correlates with strain echocardiography and biomarkers. Eur J Nucl Med Mol Imaging 2021;48:1822-32. DOI PubMed PMC
17. Steen H, Giusca S, Montenbruck M, et al. Left and right ventricular strain using fast strain-encoded cardiovascular magnetic resonance
for the diagnostic classification of patients with chronic non-ischemic heart failure due to dilated, hypertrophic cardiomyopathy or
cardiac amyloidosis. J Cardiovasc Magn Reson 2021;23:45. DOI PubMed PMC
18. Giusca S, Steen H, Montenbruck M, et al. Multi-parametric assessment of left ventricular hypertrophy using late gadolinium
enhancement, T1 mapping and strain-encoded cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2021;23:92. DOI
PubMed PMC
19. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93. DOI
PubMed
20. Duca F, Kammerlander AA, Panzenböck A, et al. Cardiac magnetic resonance T mapping in cardiac amyloidosis. JACC Cardiovasc
1
Imaging 2018;11:1924-6. DOI PubMed
21. Burrage MK, Ferreira VM. Cardiovascular magnetic resonance for the differentiation of left ventricular hypertrophy. Curr Heart Fail
Rep 2020;17:192-204. DOI PubMed PMC
22. Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac
amyloidosis. Circulation 2015;132:1570-9. DOI PubMed PMC
23. Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a
systematic review and meta-analysis. BMC Cardiovasc Disord 2016;16:129. DOI PubMed PMC
24. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC
Cardiovasc Imaging 2010;3:155-64. DOI PubMed
25. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol
2017;70:466-77. DOI PubMed
26. Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic
resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013;6:392-8. DOI PubMed
27. Sado DM, Flett AS, Banypersad SM, et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in
health and disease. Heart 2012;98:1436-41. DOI PubMed
28. Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC
Cardiovasc Imaging 2013;6:488-97. DOI PubMed
29. Fontana M, Banypersad SM, Treibel TA, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging
2014;7:157-65. DOI PubMed
30. Baggiano A, Boldrini M, Martinez-Naharro A, et al. Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC
Cardiovasc Imaging 2020;13:69-80. DOI PubMed
31. Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an
equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2013;6:34-9. DOI PubMed
32. Martinez-Naharro A, Kotecha T, Norrington K, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC
Cardiovasc Imaging 2019;12:810-9. DOI PubMed